
100
Stenographic Writing Device – Phonetic Symbols
RS232-RS232 Connection
Computer Assisted Translation Software Program Phonetic Symbols translated into English Text
RS232-RS232 Connection
TCP Port Port 7000
Internet
TCP Port Port 7000
English Text parsed into paragraphs & transmitted to the TextReceiver
Text Converted into HTML in Real-Time and written
102
Transcript Production System
Server Storage for Presentation Text converted into HTML
Client Transcript Sytem
TCP Port Port 80
Internet
TCP Port Port 80
Client-Side Application
Internet Information Server
Server Side Application
Real-Time Presentation Text provided in HTML to the Client
TCP Port Port 80
TCP Port Port 80
104

FIGURE 1


1
Stenographic Writing Device
–
Phonetic Symbols
106
102
2
RS232-RS232 Connection
108
3
Computer Assisted Translation Software Program
Phonetic Symbols translated into English Text
4
RS232-RS232 Connection
5
~~iBEAM TextSender~~
English Text parsed into paragraphs & transmitted to the TextReceiver
110
TCP Port
Port 7000
6
Internet
7
TCP Port
Port 7000
112
~~iBEAM TextReceiver~~
Text Converted into HTML in Real-Time and written
8
9
Server Storage for Presentation Text converted into HTML
114

FIGURE 2


104
114
Server Storage for Presentation Text converted into HTML
118
1
11
12
15
16
TCP Port
Port 80
Internet
TCP Port
Port 80
13
~~IBCRM~~ Internet Information Server
120
10
~~IBCRM NextEvent~~ Client-Side Application
116
NextEvent Server Side Application
Real-Time Presentation Text provided in HTML to the Client
TCP Port
Port 80
TCP Port
Port 80
18
17
14
19

FIGURE 3



FIGURE 4 (Browser screenshot)

Page 4 of 5 Exhibit 1004



FIGURE 5 (Browser Screenshot)

Page 1 of 1


400
FILE EDIT
Onyx Pharmaceuticals (ONXX) President Hollings - 11/21/00
402
Additional Text Not Available
404
408
Introduction: Renton discusses the company's treatment for cancer. He says this technology modifies the virus by killing tumor cells and not healthy cells. He is hopeful to extend the treatment beyond head and neck cancers.
410
Bill: Shares of biotech firm Onyx Pharmaceuticals continue to climb for the second day in a row on positive news about an experimental drug that appears to help shrink head and neck tumors. The latest research shows the drug Onyx-15 is working on tumors that failed to respond to other therapies. Joining me now to talk about the development is Hollings Renton, CEO of Onyx Pharmaceuticals. He's in sunny and warm, Palm Springs, California. How have you been? It is nice to see you again.
It is nice to you see you, Bill.
Bill: Tell me about the latest developments and where are you in the latest trials at this point?
Hollings: What we just published in cancer research this week is in the end-stage patients with head and neck cancer we were able to shrink 50% of the injected tumors in 20% of the patients in the study.
Bill: Describe very briefly how this works.
Hollings: This technology sets Onyx apart from all other cancer therapy companies in that we are able to modify a virus, so it only replicates and kills tumor cells and does not damage normal cells.
406

FIGURE 6